Abnormal aldosterone physiology and cardiometabolic risk factors

Hypertension

Volumn 61, Issue 4, 2013, Pages 886-893

  Vaidya, Anand ^a   Underwood, Patricia C ^a   Hopkins, Paul N ^b   Jeunemaitre, Xavier ^c   Ferri, Claudio ^d   Williams, Gordon H ^a   Adler, Gail K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

adrenal; aldosterone; metabolic syndrome; physiology; renin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; CORTICOTROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; POTASSIUM; SODIUM; TRIACYLGLYCEROL;

ADULT; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE URINE LEVEL; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOMETABOLIC RISK; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM INTAKE; SODIUM RESTRICTION;

ALDOSTERONE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RENIN; RISK FACTORS; UNITED STATES;

EID: 84875217870     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00662     Document Type: Article

References (39)

1. Briet M, Schiffrin EL. The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep. 2011;13:163-172.
2. Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension. 2008;51:1252-1258.
3. Tirosh A, Garg R, Adler GK. Mineralocorticoid receptor antagonists and the metabolic syndrome. Curr Hypertens Rep. 2010;12:252-257.
4. Whaley-Connell A, Johnson MS, Sowers JR. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis. 2010;52:401-409.
5. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, März W. Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Am J Kidney Dis. 2011;57:403-414.
6. Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, Fox CS, Meigs JB, Levy D, Larson MG, Selhub J, D'Agostino RB Sr, Wang TJ, Vasan RS. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. 2007;116:984-992.
7. Bentley-Lewis R, Adler GK, Perlstein T, Seely EW, Hopkins PN, Williams GH, Garg R. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab. 2007;92:4472-4475.
8. Garg R, Hurwitz S, Williams GH, Hopkins PN, Adler GK. Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab. 2010;95:1986-1990.
9. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, Shamlaye C, Burnier M. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006;48:239-245.
10. Hannemann A, Wallaschofski H, Lüdemann J, Völzke H, Markus MR, Rettig R, Lendeckel U, Reincke M, Felix SB, Empen K, Nauck M, Dörr M. Plasma aldosterone levels and aldosterone-to-renin ratios are associated with endothelial dysfunction in young to middle-aged subjects. Atherosclerosis. 2011;219:875-879.
11. Goodfriend TL, Egan B, Stepniakowski K, Ball DL. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension. 1995;25:30-36.
12. Rossi GP, Belfiore A, Bernini G, et al; Primary Aldosteronism Prevalence in hYpertension Study Investigators. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab. 2008;93:2566-2571.
13. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res. 1999;7:355-362.
14. Ferri C, Bellini C, Desideri G, Valenti M, De Mattia G, Santucci A, Hollenberg NK, Williams GH. Relationship between insulin resistance and nonmodulating hypertension: linkage of metabolic abnormalities and cardiovascular risk. Diabetes. 1999;48:1623-1630.
15. Gaboury CL, Hollenberg NK, Hopkins PN, Williams R, Williams GH. Metabolic derangements in nonmodulating hypertension. Am J Hypertens. 1995;8:870-875.
16. Raji A, Williams GH, Jeunemaitre X, Hopkins PN, Hunt SC, Hollenberg NK, Seely EW. Insulin resistance in hypertensives: effect of salt sensitivity, renin status and sodium intake. J Hypertens. 2001;19:99-105.
17. Vaidya A, Sun B, Larson C, Forman JP, Williams JS. Vitamin D3 therapy corrects the tissue sensitivity to angiotensin II akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study. J Clin Endocrinol Metab. 2012;97:2456-2465.
18. Underwood PC, Chamarthi B, Williams JS, Vaidya A, Garg R, Adler GK, Grotzke MP, Staskus G, Wadwekar D, Hopkins PN, Ferri C, McCall A, McClain D, Williams GH. Nonmodulation as the mechanism for salt sensitivity of blood pressure in individuals with hypertension and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97:3775-3782.
19. Price DA, De'Oliveira JM, Fisher ND, Williams GH, Hollenberg NK. The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus. Am J Hypertens. 1999;12(4 pt 1):348-355.
20. Vaidya A, Forman JP, Underwood PC, Hopkins PN, Williams GH, Pojoga LH, Williams JS. The influence of body-mass index and renin-angiotensin- aldosterone system activity on the relationship between 25-hydroxyvitamin d and adiponectin in Caucasian men. Eur J-Endocrinol.
21. Pojoga LH, Underwood PC, Goodarzi MO, et al. Variants of the caveolin- 1 gene: a translational investigation linking insulin resistance and hypertension. J Clin Endocrinol Metab. 2011;96:E1288-E1292.
22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-553.
23. Vimaleswaran KS, Radha V, Jayapriya MG, Ghosh S, Majumder PP, Rao MR, Mohan V. Evidence for an association with type 2 diabetes mellitus at the PPARG locus in a South Indian population. Metab Clin Exp. 2010;59:457-462.
24. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003;26: 575-581.
25. Shoback DM, Williams GH, Hollenberg NK, Davies RO, Moore TJ, Dluhy RG. Endogenous angiotensin II as a determinant of sodium-modulated changes in tissue responsiveness to angiotensin II in normal man. J Clin Endocrinol Metab. 1983;57:764-770.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
27. Trout KK, Homko C, Tkacs NC. Methods of measuring insulin sensitivity. Biol Res Nurs. 2007;8:305-318.
28. Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension. 2012;59: 893-898.
29. Okosun IS, Liao Y, Rotimi CN, Prewitt TE, Cooper RS. Abdominal adiposity and clustering of multiple metabolic syndrome in White, Black and Hispanic Americans. Ann Epidemiol. 2000;10:263-270.
30. Sartorio A, Agosti F, Adorni F, Pera F, Lafortuna CL. Effect of age, degree and distribution of adiposity on the prevalence of the metabolic syndrome in a cohort of obese Italian women. Diabetes Res Clin Pract. 2007;78:225-233.
31. Schmidt MI, Duncan BB, Watson RL, Sharrett AR, Brancati FL, Heiss G. A metabolic syndrome in whites and African-Americans. The Atherosclerosis Risk in Communities baseline study. Diabetes Care. 1996;19:414-418.
32. Vaes B, Delgado V, Bax J, Degryse J, Westendorp RG, Gussekloo J. Diagnostic accuracy of plasma NT-proBNP levels for excluding cardiac abnormalities in the very elderly. BMC Geriatr. 2010;10-85.
33. Shoback DM, Williams GH, Moore TJ, Dluhy RG, Podolsky S, Hollenberg NK. Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. J Clin Invest. 1983;72:2115-2124.
34. Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X, Plouin PF. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2009;53:605-610.
35. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Corrêa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59:1069-1078.
36. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, Hauner H, McCann SM, Scherbaum WA, Bornstein SR. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA. 2003;100:14211-14216.
37. Goodfriend TL, Egan BM, Kelley DE. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids. 1999;60:401-405.
38. Dluhy RG, Axelrod L, Underwood RH, Williams GH. Studies of the control of plasma aldosterone concentration in normal man. II. Effect of dietary potassium and acute potassium infusion. J Clin Invest. 1972;51:1950-1957.
39. Williams GH, Cain JP, Dluhy RG, Underwood RH. Studies of the control of plasma aldosterone concentration in normal man. I. Response to posture, acute and chronic volume depletion, and sodium loading. J Clin Invest. 1972;51:1731-1742.